1 / 30

Insulin Sensitizers: Surrogate and Clinical Outcomes Studies

Insulin Sensitizers: Surrogate and Clinical Outcomes Studies. Metformin improves endothelial function. Metformin 1000 mg ( 3 months). Placebo. 400. 350. *. 300. 250. Increase in forearm blood flow (%). 200. *. 150. 100. *. 50. 0. 3. 10. 30. 3. 10. 30.

gphelps
Download Presentation

Insulin Sensitizers: Surrogate and Clinical Outcomes Studies

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Insulin Sensitizers: Surrogate and Clinical Outcomes Studies

  2. Metformin improves endothelial function Metformin 1000 mg (3 months) Placebo 400 350 * 300 250 Increase in forearm blood flow (%) 200 * 150 100 * 50 0 3 10 30 3 10 30 Acetylcholine (g/min) Before treatment After treatment Mather KJ et al. J Am Coll Cardiol. 2001;37:1344-50. * P = 0.0027 vs placebo

  3. PPAR activation improves renal endothelial function and reduces proteinuria N = 19 with type 2 diabetes with/without microalbuminuria P < 0.05 P < 0.05 140 133 120 Treatment with rosiglitazone was followed by 60% reductions in albuminuria and proteinuria in diabetic patients with microalbuminuria. 119 120 103 100 GFR(mL/min) 80 60 40 20 0 Placebo Rosiglitazone Nateglinide Rosiglitazone Microalbuminuria No microalbuminuria Pistrosch F et al. Diabetes. 2005;54:2206-11.

  4. PPAR activation normalizes coronary vasomotor abnormalities in insulin resistance N = 16 with insulin resistance; rosiglitazone 8 mg for 3 months P < 0.01 50 P < 0.01 40 40.3(±31.3) MBF* (%) 30 20 19.6(±24.3) 10 8.7(±18.9) 0 Pre-Treatment Post-Treatment Off-Treatment Quiñones MJ et al. Ann Intern Med. 2004;140:700-8. * from rest

  5. PPAR activation: Consistent reduction in carotid atherosclerosis Patients (n)duration Study (year) Treatments  IMT (mm) 0.080, troglitazone0.027, usual careP < 0.001 Type 2 diabetes (n = 135)6 mos Minamikawa(1998) Troglitazone 400 mgUsual care Type 2 diabetes(n = 106) 6 mos 0.084, troglitazone0.022, usual careP < 0.001 Koshiyama(2001) Pioglitazone 30 mgUsual care 0.012, rosiglitazone0.0031, placeboP = 0.03 Stable CAD(n = 92)12 mos Sidhu(2004) Rosiglitazone 8 mgPlacebo 0.054, pioglitazone0.011, glimepirideP < 0.001 Langenfeld(2005) Type 2 diabetes(n = 173)6 mos Pioglitazone 45 mgGlimepiride 2.7 mg Minamikawa J et al. J Clin Endocrinol Metab. 1998;83:1818-20.Koshiyama H et al. J Clin Endocrinol Metab. 2001;86;3452-6.Sidhu JS et al. Arterioscler Thromb Vasc Biol. 2004;24:930-4.Langenfeld MR et al. Circulation. 2005;111:2525-31.

  6. PPAR activation blunts progression of carotid atherosclerosis in stable CAD N = 92 without diabetes 0.04 PlaceboProgression rate = 0.031 mm/48 wks 0.03 0.02  Carotid IMT (mm) Rosiglitazone 8 mgProgression rate = 0.012 mm/48 wks 0.01 0 –0.01 0 24 48 Time (weeks) Adapted from Sidhu JS et al. Arterioscler Thromb Vasc Biol. 2004;24:930-4. P = 0.03

  7. PPAR activation blunts progression of carotid atherosclerosis N = 173 with type 2 diabetes 0.08 ns 0.04 0.00 CarotidIMT (mm) P < 0.001 –0.04 –0.08 –0.12 P < 0.005 –0.16 0 12 24 Weeks Glimepiride 2.7 mg Pioglitazone 45 mg Langenfeld MR et al. Circulation. 2005;111:2525-31.

  8. Additive effect of statin and PPAR activation on atherosclerosis † ‡ Rabbit model Changes in maximal vessel wall thickness High- cholesterol diet (n = 6) 20 Normal diet +simvastatin + PPAR agonist * (n = 6) Normal diet + PPAR-agonist* (n = 7) Normal diet +simvastatin (n = 6) 10 Normal diet(n = 6) 0  (%) P < 0.01 † † –10 † ‡ –20 –30 P = 0.04 P = 0.03 *L-805645 †P < 0.05 vs high-cholesterol diet ‡P < 0.05 vs normal diet Corti R et al. J Am Coll Cardiol. 2004;43:464-73.

  9. PPAR activation reduces intimal hyperplasia Balloon injury in mouse model Rosiglitazone 8 mg/kg Control 4 3.1 3 I/M ratio(%) P < 0.001 2 0.98 1 0 Intimal area Medial area Rosiglitazone Control I/M = Wang C-H et al. Circulation. 2004;109:1392-400.

  10. PPAR activation: Consistent  in neointimal proliferation (stented patients with T2D) Intimal index (%) Trialduration Study, year (n) Treatments Randomization 2 days prior 6 mos Diet ± Troglitazone 400 mg 27.1, troglitazone49.0, controlP < 0.001 Takagi,2000(n = 52) Ins/SU/Acar ±Troglitazone400 mg 6 mos 1 day prior 39.1, troglitazone71.5, controlP < 0.0001 Takagi,2002(n = 55) 6 mos Takagi,2003(n = 44) 8 days prior 28%, pioglitazone48%, controlP < 0.0001 Ins/SU/Acar ±Pioglitazone 30 mg Trend to benefit Placebo Rosiglitazone4 mg/ 8 mg After stenting Osman,2004(n = 16) 6 mos(first mo at 4 mg) Takagi T et al. J Am Coll Cardiol. 2000;36:1529-35.Takagi T et al. Am J Cardiol. 2002;89;318-22.Takagi T et al. Am Heart J. 2003;146:e5. Osman A et al. Am Heart J. 2004;147:e23. Intimal area Intimal index = Stent area

  11. PPAR activation reduces in-stent restenosis N = 95 with type 2 diabetes 25 P = 0.03 21 20 15 Restenosis (% stents) 9 10 5 0 Control(n = 45) Rosiglitazone*(n = 38) *8-mg dose before catheterization; 4 mg daily thereafter Choi D et al. Diabetes Care. 2004;27:2654-60.

  12. Preliminary data support reduction in MIwith PPAR activation Favors oral therapy Favors insulin 0.62 Sulfonylurea 0.61 Metformin Sulfonylurea + metformin 0.56 0.51 Thiazolidinedione 0.5 0.75 1 1.25 0.25 Odds ratio for MI Koro CE et al. Diabetes. 2004;53(suppl 2):A247.

  13. PPAR activation associated with lower mortality N = 16,417 with diabetes and HF 1.0 0.9 0.8 Proportion of patientssurviving Thiazolidinedione (n = 2226) 0.7 13% Relative risk reduction 0.6 No insulin sensitizer (n = 12,069) 0.5 0 50 100 150 200 250 300 350 Time (days) Masoudi FA et al. Circulation. 2005;111:583-90.

  14. Metformin associated with lower mortality N = 16,417 with diabetes and HF 1.0 0.9 0.8 Proportion of patientssurviving Metformin (n = 1861) 0.7 13% Relativerisk reduction No insulin sensitizer (n = 12,069) 0.6 0.5 0 50 100 150 200 250 300 350 Time (days) Masoudi FA et al. Circulation. 2005;111:583-90.

  15. Neutral effect of PPAR activationand metformin on hospital readmission N = 16,417 with diabetes and HF All-cause HF TZD 1.04 (0.99–1.10) 1.06 (1.00–1.12) Metformin 0.94 (0.89–1.01) 0.92 (0.86–0.99) Hospital readmission TZD = thiazolidinedione Masoudi FA et al. Circulation. 2005;111:583-90.

  16. Thiazolidinediones in patients with type 2 diabetes and HF AHA/ADA consensus statement summary • NYHA class I/II HF: Thiazolidinediones may be used cautiously, with initiation of treatment at the lowest dose and gradual dose escalation • Allow more time than usual to achieve target A1C • NYHA class III/IV HF: Thiazolidinediones should not be used at this time Nesto RW et al. Circulation. 2003;108:2941-8.

  17. Mortality benefit with combined insulin-sensitizing therapy 8872 acute MI patients, mean age 76.4 years, discharged on glucose-lowering medication No insulin sensitizer (n = 6641)Thiazolidinediones (n = 1273) Metformin (n = 819) TZD + MET (n = 139) 1.00 0.95 Proportion of patientssurviving 0.90 48% Relativerisk reduction 0.85 0.80 0 50 100 150 200 250 300 350 Days from discharge Inzucchi SE et al. Diabetes Care. 2005;28:1680-9.

  18. Insulin sensitizers vs other glucose-lowering agents following AMI 8872 acute MI patients, mean age 76.4 years, discharged on glucose-lowering medication Metformin TZD Both Mortality 0.92 (0.81–1.06) 0.92 (0.80–1.05) 0.52 (0.34–0.82) Myocardial infarction readmission 1.02 (0.86–1.20) 0.92 (0.77–1.10) 0.88 (0.56–1.37) Heart failurereadmission 1.06 (0.95–1.18) 1.17 (1.05–1.30) 1.24 (0.94–1.63) All-cause readmission 1.04 (0.96–1.13) 1.09 (1.00–1.20) 1.06 (0.87–1.30) Inzucchi SE et al. Diabetes Care. 2005;28:1680-9.

  19. UKPDS: Risk reduction with metformin in overweight patients N = 4075 with type 2 diabetes Aggregate endpoints P* Favors metforminor intensive Favors conventional All-cause mortality Metformin Intensive Myocardial infarction Metformin Intensive Stroke Metformin Intensive 0.021 0.021 0.021 0.1 1 10 Relative risk reduction(95% CI) *metformin vs intensive therapy UKPDS Group. Lancet. 1998;352:854-65.

  20. Evolution of clinical evidence supporting PPAR activation Surrogate outcomes studies Ongoing clinical outcomes studies Large observational studies 2000 2005 and beyond Mortality in patients with diabetes + HF or AMI Endothelialfunction Carotid atherosclerosis Restenosis

  21. Anticipated results from large multicenter trials in diabetes and prediabetes NAVIGATOR VADT RECORD ACT-NOW PERISCOPE ADOPTAPPROACH CHICAGO ACCORDBARI-2DORIGIN DREAM PROactive 2005 2006 2007 2008 2009 Clinical outcomes Surrogate outcomes

  22. PROactive: Study design Objective: Assess the effects of pioglitazone on reducing macrovascular events in type 2 diabetes Design: Randomized double-blind, controlled outcome Population: N = 5238 with type 2 diabetes and history of macrovascular disease Treatment: Pioglitazone (up to 45 mg) or placebo Primary outcome: Composite of all-cause mortality, MI, ACS, coronary or peripheral revascularization, amputation, stroke Secondary outcomes: Individual components of primary outcome, CV mortality Follow-up:4 years Charbonnel B et al. Diabetes Care. 2004;27:1647-53. Dormandy JA et al. Lancet. 2005;366:1279-89.

  23. PROactive: Baseline CV history % Dormandy JA et al. Lancet. 2005;366:1279-89.

  24. PROactive: CV medications at study entry % Dormandy JA et al. Lancet. 2005;366:1279-89.

  25. PROactive: Reduction in primary outcome All-cause mortality, MI, ACS, coronary or peripheral revascularization, amputation, stroke 25 10% Relative risk reduction HR* 0.90 (0.80–1.02)P = 0.095 Placebo(572 events) 20 Pioglitazone(514 events) 15 Proportionof events(%) 10 5 0 0 6 12 18 24 30 36 Time from randomization Number at risk Pioglitazone 2488 2373 2302 2218 2146 348 Placebo 2530 2413 2317 2215 2122 345 *Unadjusted Dormandy JA et al. Lancet. 2005;366:1279-89.

  26. PROactive: Reduction in secondary outcome All-cause mortality, MI (excluding silent MI), stroke 25 20 Placebo(358 events) 16% Relative risk reduction HR* 0.84 (0.72–0.98)P = 0.027 15 Proportionof events(%) 10 Pioglitazone(301 events) 5 0 0 6 12 18 24 30 36 Time from randomization Number at risk Pioglitazone 2536 2487 2435 2381 2336 396 Placebo 2566 2504 2442 2371 2315 390 *Unadjusted Dormandy JA et al. Lancet. 2005;366:1279-89.

  27. PROactive: Summary • Pioglitazone added to standard antidiabetic and CV therapies showed: • 10% RRR in primary outcome – Composite all-cause mortality, nonfatal MI (including silent MI), stroke, ACS, leg amputation, coronary or leg revascularization • 16% RRR in secondary outcome – All-cause mortality, nonfatal MI (excluding silent MI) or stroke • No difference between groups in HF mortality • Continued divergence in survival curves – Greater benefit with longer treatment duration hypothesized PROactive results support use of PPAR modulator in patients with diabetes at high CVD risk – May improve CVD outcomes and need to add insulin Dormandy JA et al. Lancet. 2005;366:1279-89.

  28. DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication Objective: Assess efficacy of rosiglitazone and ramipril in diabetes prevention Design: N = 5269 with IGT or IFG, randomized (2x2 factorial design) to Treatment: Rosiglitazone 8 mg vs placebo or ramipril 15 mg vs placebo Primary outcomes: New-onset diabetes and all-cause mortality Secondary outcomes: Combined MI, stroke, CV death, PCI/CABG, HF, angina, ventricular arrhythmia Combined microalbuminuria/macroalbuminuria development, 30% decrease in CrCl STARR substudy: Change in carotid atherosclerosis Follow-up: 4 years (anticipated) Completion: 2006 The DREAM Trial Investigators. Diabetologia. 2004;47:1519-27.

  29. DREAM: Baseline characteristics Age (years) 54.7 Hypertension (%) 43.5 Hyperlipidemia (%) 35.5 BP (mm Hg) 136/83 BMI (kg/m2) 30.5 Waist circumference (inches) Men 34.3 Women 32.6 The DREAM Trial Investigators. Diabetologia. 2004;47:1519-27.

  30. ADOPT: Study design ADiabetes Outcome Progression Trial Objective: Assess effect on glucose control of rosiglitazone, metformin, or glyburide monotherapy Design: N = ~3600 with type 2 diabetes of 3 years duration, drug-naïve Treatment: Randomized to rosiglitazone 8 mg, metformin 2 g, or glyburide 15 mg Primary outcome: Time to need for combination therapy Secondary outcomes:-cell function, insulin sensitivity, dyslipidemia, albumin excretion, PAI-1, fibrinogen, CRP Follow-up: 4 years Completion: 2007 Viberti G et al. Diabetes Care. 2002;25:1737-43.

More Related